hetrombopag: Clinical Trials

7 trials of hetrombopag, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 7 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 22Unknown 1, Withdrawn 1

Follow hetrombopag: new trials by email Literature Review of hetrombopag trials Research Report on hetrombopag

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study
Hetrombopag, Placebo - Thrombocytopenia, Hepatic Interventional Procedure
Phase 3Not yet recruitingZhongda Hospital1082026-10-152026-11-09
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Hetrombopag, Hetrombopag plus Placebo, Placebo - Chemotherapy-Induced Thrombocytopenia
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.2132023-04-252025-04-16
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Hetrombopag, Matching placebo - Chemotherapy-Induced Thrombocytopenia
Phase 3WithdrawnJiangsu HengRui Medicine Co., Ltd.2022-04-152023-09-28
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia
Hetrombopag, Stanozolol Tablets - MDS
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital502021-10-012021-09-24
Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
Hetrombopag - Aplastic Anemia, Drug Effect
Phase 2 / Phase 3WithdrawnPeking Union Medical College Hospital2021-10-012026-06-08
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
Hetrombopag, Placebo - Immune Thrombocytopenia
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.1002021-03-292025-07-18
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Hetrombopag, Placebo - Chemotherapy-Induced Thrombocytopenia
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.1292019-11-062025-05-16

Conditions studied

Anemia, Aplastic (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)  ·  Thrombocytopenia (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (4)  ·  Peking Union Medical College Hospital (2)  ·  Zhongda Hospital (1)

Countries

China (5)

Top investigators

Bing Han, Docter (1)  ·  Bing Han, Master (1)  ·  Gao-jun Teng (1)

Results publications

PMID 38882443, PMID 41952212